Natera announces new study as part of I-SPY 2 trial

Natera announced a new study as part of the I-SPY 2 trial, sponsored and operated by Quantum Leap Healthcare Collaborative, that will use Signatera, Natera’s personalized and tumor-informed molecular residual disease, or MRD, test, to monitor response to neoadjuvant therapy in breast cancer patients across all subtypes. This prospective study, in which 600 patients will be monitored in real time, will support efforts to establish circulating tumor DNA, or ctDNA, as a composite endpoint and generate additional data on post-surgical ctDNA status in patients treated with neoadjuvant therapy. It expands on the existing collaboration with the ISPY-2 consortium that has led to the publication of multiple studies validating the use of Signatera for neoadjuvant response monitoring and predicting recurrence risk, including studies published in Cancer Cell1 and Annals of Oncology.